- abnormal response/metabolism to endogenous compounds / MGI
- decreased circulating interleukin-6 level / MGI
- decreased sensitivity to induced morbidity/mortality / MGI
- decreased physiological sensitivity to xenobiotic / MGI
- decreased sensitivity to xenobiotic induced morbidity/mortality / MGI
- abnormal sleep pattern / MGI
- impaired central nervous system regeneration / MGI
- increased sensitivity to induced cell death / MGI
- increased susceptibility to bacterial infection induced morbidity/mortality / MGI
- impaired humoral immune response / MGI
- decreased susceptibility to bacterial infection / MGI
- decreased circulating alanine transaminase level / MGI
- abnormal Peyer's patch morphology / MGI
- abnormal immune system physiology / MGI
- abnormal lymph node B cell domain morphology / MGI
- abnormal Peyer's patch follicle morphology / MGI
- increased susceptibility to bacterial infection / MGI
- decreased susceptibility to experimental autoimmune encephalomyelitis / MGI
- increased susceptibility to parasitic infection / MGI
- increased susceptibility to type I hypersensitivity reaction / MGI
- decreased Peyer's patch number / MGI
- absent follicular dendritic cells / MGI
- decreased IgG1 level / MGI
- decreased interleukin-6 secretion / MGI
CBA.B6-Tnfrsf1atm1Blt Tg(CD2-TNF/HBB)211Gkl/Flmg
Status | Available to order |
EMMA ID | EM:11021 |
International strain name | CBA.B6-Tnfrsf1atm1Blt Tg(CD2-TNF/HBB)211Gkl/Flmg |
Alternative name | CBA.B6-Tnfrsf1a |
Strain type | Transgenic Strains |
Allele/Transgene symbol | Tg(CD2-TNF/HBB)211Gkl |
Gene/Transgene symbol | Tg(CD2-TNF/HBB)211Gkl |
Information from provider
Provider | George Kollias |
Provider affiliation | B.S.R.C. |
Genetic information | The transgene comprises the T cell specific human CD2 gene locus control region (LCR) linked to the entire coding region of the human TNF gene with polyadenylation signal and flanking sequences replaced by those of the human hemoglobin beta (HBB) gene. This modification does not interfere with correct translation. |
Phenotypic information | Homozygous:embryonic lethalityHeterozygous:Lethal wasting syndrome and lymphoid abnormalities. 80-100% mortality occurs within 71-127 days. Affected mice become hunched and unhealthy in appearance typically between 2 and 4 weeks of age. They demonstrate poor growth rates and subsequently severe weight loss. Line is maintained in TNFR1+/- background so that pathology is attenuated. |
References |
|
Homozygous fertile | no |
Homozygous viable | no |
Homozygous matings required | no |
Immunocompromised | no |
Information from EMMA
Archiving centre | B.S.R.C. Alexander Fleming, Vari, Greece |
Animals used for archiving | heterozygous CBA x C57BL/6, wild-type (CBA x C57BL/6)F1 |
Stage of embryos | Morula |
Disease and phenotype information
Orphanet associated rare diseases, based on orthologous gene matching
- Tumor necrosis factor receptor 1 associated periodic syndrome / Orphanet_32960
MGI phenotypes (allele matching)
Literature references
- Wasting, ischemia, and lymphoid abnormalities in mice expressing T cell-targeted human tumor necrosis factor transgenes.;Probert L, Keffer J, Corbella P, Cazlaris H, Patsavoudi E, Stephens S, Kaslaris E, Kioussis D, Kollias G, ;1993;Journal of immunology (Baltimore, Md. : 1950);151;1894-906; 8345187
INFRAFRONTIER® and European Mouse Mutant Archive - EMMA® are registered trademarks at the European Union Intellectual Property Office (EUIPO).